[
    [
        {
            "time": "2019-05",
            "original_text": "板块分化后的投资策略 ——兴证医药2019年5月投资月报",
            "features": {
                "keywords": [
                    "板块分化",
                    "投资策略",
                    "兴证医药"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "板块分化后的投资策略 ——兴证医药2019年5月投资月报",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2019-Q1",
            "original_text": "创业板一季度业绩呈企稳迹象 持续增长态势可期",
            "features": {
                "keywords": [
                    "创业板",
                    "一季度",
                    "业绩企稳",
                    "持续增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "创业板"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "创业板一季度业绩呈企稳迹象 持续增长态势可期",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-Q1",
            "original_text": "【国盛医药张金洋团队】年报季报验证医药从野蛮扩张到结构优化，继续推荐医药流通",
            "features": {
                "keywords": [
                    "国盛医药",
                    "年报季报",
                    "结构优化",
                    "医药流通"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国盛医药张金洋团队】年报季报验证医药从野蛮扩张到结构优化，继续推荐医药流通",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        }
    ]
]